Expanding Clinical Trials

Stereotactic Radiosurgery for Breast Cancer

A novel, breast stereotactic radiotherapy device is now undergoing testing on an FDA approved investigation device exemption protocol. This device has immense potential as a one day, noninvasive, curative treatment for early stage breast cancer.

What is the research problem

Standard breast cancer treatment includes excision followed by several weeks of radiotherapy. Stereotactic radiosurgery has proven an effective alternative to surgery in lung/brain cancer but has yet to be explored for breast cancer.

How will your solution make a difference

Data generated from this study could revolutionize the management of early stage breast cancer. A single, noninvasive, outpatient procedure, performed in 90 minutes, could completely replace the current 11+ week standard of surgery and radiation.

What is your proposed solution

Preoperative stereotactic breast radiosurgery will be piloted with this novel device. To develop a completely non-surgical approach to breast cancer, we must identify predictors of response to treatment. Extensive pre- and post-radiation functional MRI, serum biomarker sampling, and pathologic assessment will help to identify surrogates for complete pathologic response (pCR). We expect a pCR in 80+% of patients as seen in other disease sites.

Voting

0 votes
Ideate
Idea No. 858